Chronic Liver Diseases Therapeutics Market, by Treatment Type (Antiviral Drugs, Immunosuppressant’s, Vaccines, Immunoglobulin’s, Corticosteroids, Targeted Therapy, and Chemotherapy), by Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liv

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	154 Pages	Coherent Market Insights	February, 2022	CMI17072923

Best Price Guarantee
Price	from $4,500
Length	154 Pages
Publisher	Coherent Market Insights
Published Date	February, 2022
SKU	CMI17072923

Chronic Liver Diseases Therapeutics Market, by Treatment Type (Antiviral Drugs, Immunosuppressant’s, Vaccines, Immunoglobulin’s, Corticosteroids, Targeted Therapy, and Chemotherapy), by Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease (NAFLD), Cancer, Genetic Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

The liver is the largest solid internal organ of the body which performs various roles that include creation of bile for food digestion, converting food into energy, and maintaining an adequate level of the chemical in the body that stores nutrients for all cellular and biological activities. Therefore, improper functioning of the liver can cause many severe diseases which include hepatitis A, B, C, primary cirrhosis, and tumors. Some of the paramount reasons for improper functioning of the liver are obesity, excessive alcohol consumption, and genetic disorder. The treatment option available to treat liver diseases includes antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Moreover, chronic liver diseases include hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.

Market Dynamics

The increasing population of chronic liver diseases, rising research and development activities for the development of novel technology for the treatment of liver diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period.

For instance, Primary Sclerosing Cholangitis (PSC), is a chronic disease in which the bile duct inside and outside the liver become inflamed and scarred, eventually narrowed and blocked, subsequently, bile builds up in the liver and causes liver damage. According to National Institute of Health Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide prevalence of 25%. In the U.S, NAFLD and its subtype, nonalcoholic steatohepatitis, affect 30% and 5% of the population respectively.

Key features of the study:

This report provides an in-depth analysis of the global chronic liver diseases therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic liver diseases therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global chronic liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic liver diseases therapeutics market

Detailed Segmentation:

Global Chronic Liver Diseases Therapeutics Market, By Treatment Type:
Antiviral Drugs
Immunosuppressants
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy
Global Chronic Liver Diseases Therapeutics Market, By Disease Type:
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorder
Others
Global Chronic Liver Diseases Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Chronic Liver Diseases Therapeutics Market, By Region:
North America
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Astellas Pharma Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline Plc
Hoffmann-La Roche Ltd
Merck & Co. Inc
Novartis AG
Sanofi S.A
Pfizer Inc
Takeda Pharmaceutical
Valeant Pharmaceuticals
Watson Pharmaceuticals
Theratechnologies Inc
Alnylam Pharmaceuticals, Inc
Protagonist Therapeutics, Inc
Dicerna Pharmaceuticals, Inc
Endo International
Provectus Biopharmaceuticals Inc
MAX BioPharma, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By Treatment Type; Market Snippet, By Disease Type; Market Snippet, By Distribution Channel; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Pipeline Analysis; PEST Analysis; Regulatory Scenario; Market Trends; Key Highlights; Reimbursement Scenario; Mergers & Acquisitions
4. Global Chronic Liver Diseases Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic: Economic Impact; Impact on Clinical Trials and Drug Development; Government Initiatives
5. Global Chronic Liver Diseases Therapeutics Market, By Treatment Type, 2017 – 2030, (US$ Mn): Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2018 – 2030; Segment Trends; Antiviral Drugs; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Immunosuppressants; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Vaccines; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Immunoglobulins; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Corticosteroids; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Targeted Therapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Chemotherapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
6. Global Chronic Liver Diseases Therapeutics Market, By Disease Type, 2017 – 2030, (US$ Mn): Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2018 – 2030; Segment Trends; Hepatitis; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Autoimmune Diseases; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Non-alcoholic Fatty Liver Disease (NAFLD); Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Genetic Disorders; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Other; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
7. Global Chronic Liver Diseases Therapeutics Market, By Distribution Channel, 2017 – 2030, (US$ Mn): Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2018 – 2030; Segment Trends; Hospitals Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
8. Global Chronic Liver Diseases Therapeutics Market, By Region, 2017 – 2030, (US$ Mn): Introduction; Market Share Analysis, By Region, 2022 and 2030 (%); Y-o-Y Growth Analysis, For Regions, 2018–2030; North America; Market Size and Forecast, By Treatment Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Disease Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn); U.S.; Canada; Latin America; Market Size and Forecast, By Treatment Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Disease Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Market Size and Forecast, By Treatment Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Disease Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn); Germany; U.K.; France; Italy; Spain; Russia; Rest of Europe; Asia Pacific; Market Size and Forecast, By Treatment Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Disease Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn); China; India; Japan; Australia; South Korea; ASEAN; Rest of Asia Pacific; Middle East; Market Size and Forecast, By Treatment Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Disease Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn); GCC; Israel; Rest of Middle East; Africa; Market Size and Forecast, By Treatment Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Disease Type, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn); Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn); South Africa; Central Africa; North Africa
9. Competitive Landscape: Heat Map Analysis; Market Share Analysis; Astellas Pharma Inc.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Bristol-Myers Squibb; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Gilead Sciences; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; GlaxoSmithKline Plc; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; F. Hoffmann-La Roche Ltd.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Merck & Co. Inc; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Novartis AG; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Sanofi S.A; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Pfizer Inc; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Takeda Pharmaceutical; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Valeant Pharmaceuticals; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Watson Pharmaceuticals, Inc; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Theratechnologies Inc; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Alnylam Pharmaceuticals; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Protagonist Therapeutics, Inc; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Dicerna Pharmaceuticals, Inc; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Endo International; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Provectus Biopharmaceuticals Inc; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; MAX BioPharma, Inc; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Analyst Views
10. Section: References; Research Methodology; About us and Sales Contact; *Browse 36 market data tables and 39 figures on "Global Chronic Liver Diseases Therapeutics Market” - Forecast to 2030

Global Liver Disease Treatment Market Size study & Forecast, by Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy), by Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease (NAFLD), Cancer, Genetic Disorders, Others) and Regional Analysis, 2022-2029

May, 2023 | Published by: Bizwit Research & Consulting | USD $4,950
Liver Disease Treatment Market Size, Trends, Analysis, and Outlook By Treatment (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy), By Disease (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease (NAFLD), Cancer, Genetic Disorders, Others), by Region, Country, Segment, and Companies, 2024-2030

March, 2024 | Published by: VPA Research | USD $3,980
Liver Disease Treatment Market Report by Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy), Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease (NAFLD), Cancer, Genetic Disorders, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Region 2024-2032

July, 2024 | Published by: IMARC Services Pvt. Ltd. | USD $3,899
Liver Diseases Therapeutics Market, Therapy Type (Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulin’s, Corticosteroids)

July, 2023 | Published by: Coherent Market Insights | USD $4,500
Liver Disease Therapeutic Market Report by Therapy Type (Anti-Rejection Drugs/Immunosuppressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobulins, Corticosteroids, and Anti-Viral Drugs) Disease Type (Non-alcoholic Fatty Liver Disease (NAFLD), Viral Hepatitis (B, C, D), Alcoholic Liver Disease (ALD), and Autoimmune Liver Disease (ALD)) End Users (Hospitals, Laboratories, and Others) Regions and Company Analysis 2024-2032

June, 2024 | Published by: Renub Research | USD $2,990
Liver Disease Diagnostics Market Size - By Disease Type (Hepatitis, Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease (NAFLD)), Technique (Imaging, Liver Biopsy, Endoscopy, Lab Test), End-use - Global Forecast (2024 - 2032)

January, 2024 | Published by: Global Market Insights | USD $4,850

PDF E-mail From Publisher:	$4,500
Site License Fulfilled by Publisher:	$7,000
Global Site License Fulfilled by Publisher:	$10,000

Chronic Liver Diseases Therapeutics Market, by Treatment Type (Antiviral Drugs, Immunosuppressant’s, Vaccines, Immunoglobulin’s, Corticosteroids, Targeted Therapy, and Chemotherapy), by Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liv

Research Assistance

Other tasks

Chronic Liver Diseases Therapeutics Market, by Treatment Type (Antiviral Drugs, Immunosuppressant’s, Vaccines, Immunoglobulin’s, Corticosteroids, Targeted Therapy, and Chemotherapy), by Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liv

Liver Diseases Therapeutics Market, Therapy Type (Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulin’s, Corticosteroids)

Liver Disease Diagnostics Market Size - By Disease Type (Hepatitis, Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease (NAFLD)), Technique (Imaging, Liver Biopsy, Endoscopy, Lab Test), End-use - Global Forecast (2024 - 2032)

Research Assistance

Other tasks